

# Applications of the OMOP Common Data Model for Clinical Trial Feasibility Assessment

Christopher A. Knoll<sup>1</sup>, Frank J. DeFalco<sup>1</sup>, Patrick B. Ryan, PhD<sup>1</sup>

<sup>1</sup>Janssen Research & Development, LLC, Titusville, NJ

## BACKGROUND

### The Problem:

- Randomized clinical trials are resource-intensive.
- Patient recruitment is often the most significant challenge.
  - Difficult to define and identify the target population eligible for screening.
  - Among patients identified for screening, many may fail to satisfy study inclusion criteria.
- Study protocols often based on expert perspectives or clinical intuition.
- Protocol amendments are frequently required to modify the inclusion criteria and improve recruitment performance.

### The Solution:

Implement a web based application (PSYCHIC):

- Define cohorts using rules
- Query the Common Data Model (CDM) data source and build a cohort for each rule
- Visualize the intersection between cohorts
- Provide reports on cohorts in order to refine rules
- Generate results across a distributed network that include only aggregated information without person identifiers.

## METHODS

1. Define the initial population based on an index event. This is the **Index Rule**. (Figure 1)
2. Define additional rules based on criteria relative to the **Index Date**. These are **Inclusion Rules**. (Figure 2)
3. Create the Index Cohort and Inclusion Cohorts by executing the rules against the CDMv4 data source and populate the COHORT CDM table. (Figure 3,4)
4. Generate population Visualization (Figure 5) and tabular reports for analysis. (Figure 6)
5. Refine rules if match rate is not satisfactory.

## CRITERIA DEVELOPMENT

Figure 1: Index Rule Editor

Figure 2: Inclusion Rule Editor

Figure 3: Data Source Selection

## PROTOCOL SIMULATION

Data Source	Location	Match Rate	Matching Persons	Total Persons	Execution Time
Premier	United States		Calculated: 6 of 29 cohorts	14029	
Optum Clinformatics	United States	20.23%		7220	00:19:21.347
CPRD	United Kingdom		Calculated: 1 of 29 cohorts		
Truven CCAE	United States		Calculated: 24 of 29 cohorts		
Truven MDCR	United States		Calculated: 16 of 29 cohorts		

Figure 4: Protocol Progress

Each data source is processed independently and the user can review the results without waiting for all simulations to finish.

## POPULATION VISUALIZATION




Figure 5: Treemap Visualization

The treemap displays each cohort intersection.

- One box per unique criteria combination
- Size is relative to the overall population
- Color represents number of missed criteria
  - Green: 0 miss
  - Lt. Green: 1 Miss
  - Yellow: 2 Miss
  - Orange: 3-4 Miss
  - Red: 5+ Miss

The researcher would focus on the largest boxes that have the least missed criteria.

## COHORT ANALYSIS




Figure 6A: Demographics

Figure 6B: Comorbidities

Figure 6C: Concomitant Medications

The Comorbidities and Concomitant Medications reports leverage the CDM Vocabulary to allow users to analyze cohorts using different ontologies (e.g.: SNOMED, MedDRA, RxNorm, WHO ATC)

## RESULTS

- Successfully applied to multiple clinical trials
- Leveraged 5 CDM v4 networked sources:
  - Optum ClinFormatics,
  - Truven MarketScan CCAE & MDCR
  - Premier
  - Clinical Practice Research Datalink
- Rapid results for complex protocols:
  - Contained up to 30 different criteria
  - Input into system in under an hour
  - Generated results in under an hour

## DISCUSSION

- Clinical trial feasibility assessment is an important use case for observational health data.
- The OMOP Common Data Model v4 supports many of the key data elements necessary for feasibility assessment.

- Applications, such as PSYCHIC, can be developed to enable observational data to be efficiently analyzed in a more standardized manner, facilitating immediate and direct access for interested stakeholders.

## ACKNOWLEDGEMENTS

We would like to thank Amy Loescher and Elise Felicione for their support in the implementation of PSYCHIC.

If you have an interest in becoming an external data provider, please contact us:

- Amy Loescher: [aloesch@its.jnj.com](mailto:aloesch@its.jnj.com)
- Elise Felicione: [efelicio@its.jnj.com](mailto:efelicio@its.jnj.com)
- Patrick Ryan: [pryan4@its.jnj.com](mailto:pryan4@its.jnj.com)
- Chris Knoll: [cknoll1@its.jnj.com](mailto:cknoll1@its.jnj.com)
- Frank J. DeFalco: [fdefalco@its.jnj.com](mailto:fdefalco@its.jnj.com)